Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTEM RRMS: Testosterone in RRMS
NCT03910738Phase 2Recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2027
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing Testosterone with Placebo (2 arms). Primary endpoint: Change on MRI binary criterion combining thalamic atrophy and modification in transverse diffusivity of lesions at Week 66. Started Oct 2019; status: recruiting.
02
Drugs
testosterone undecanoate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT03910738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910738.